Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NASDAQ:ESPR
- CUSIP: N/A
- Web: www.esperion.com
- Market Cap: $749.76 million
- Outstanding Shares: 22,590,000
- 50 Day Moving Avg: $36.39
- 200 Day Moving Avg: $23.37
- 52 Week Range: $9.40 - $48.21
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.61
- P/E Growth: 0.97
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $8.52 per share
- Price / Book: 3.90
- EBIDTA: ($101,960,000.00)
- Return on Equity: -21.76%
- Return on Assets: -21.07%
- Debt-to-Equity Ratio: 0.01%
- Current Ratio: 26.16%
- Quick Ratio: 26.16%
- Average Volume: 2.03 million shs.
- Beta: 2.1
- Short Ratio: 3.17
Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) released its quarterly earnings results on Monday, May, 1st. The company reported ($1.80) earnings per share for the quarter, missing analysts' consensus estimates of ($1.44) by $0.36. During the same period last year, the business earned ($0.65) EPS. View Esperion Therapeutics' Earnings History.
Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?
11 brokers have issued 12 month price targets for Esperion Therapeutics' shares. Their forecasts range from $12.50 to $67.00. On average, they anticipate Esperion Therapeutics' share price to reach $36.86 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (5/9/2017)
- 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)
Are investors shorting Esperion Therapeutics?
Esperion Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totalling 4,768,401 shares, an increase of 19.6% from the March 15th total of 3,985,852 shares. Based on an average daily volume of 6,734,352 shares, the short-interest ratio is presently 0.7 days.
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Array Biopharma (ARRY), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Repligen (RGEN), Loxo Oncology (LOXO), Blueprint Medicines Corp (BPMC), Emergent Biosolutions (EBS), Amicus Therapeutics (FOLD), Dermira (DERM), Insmed Incorporated (INSM), Coherus Biosciences (CHRS), Xencor (XNCR), Acceleron Pharma (XLRN), Insys Therapeutics (INSY), Epizyme (EPZM), Forward Pharma A/S (FWP), ZIOPHARM Oncology (ZIOP) and Aimmune Therapeutics (AIMT).
Who owns Esperion Therapeutics stock?
Esperion Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include
BOXER CAPITAL, LLC
ALTA PARTNERS VIII, L.P.
(6.50%), BB Biotech AG (6.24%), FMR LLC (5.80%), Boxer Capital LLC (5.64%) and Credit Suisse AG (3.89%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.
Who sold Esperion Therapeutics stock? Who is selling Esperion Therapeutics stock?
Esperion Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Aisling Capital LLC, Bank of America Corp DE, Martingale Asset Management L P, JPMorgan Chase & Co., Cim Investment Mangement Inc., Bellevue Group AG, Keybank National Association OH and Oxford Asset Management. View Insider Buying and Selling for Esperion Therapeutics.
Who bought Esperion Therapeutics stock? Who is buying Esperion Therapeutics stock?
Esperion Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Boxer Capital LLC, RA Capital Management LLC, Pinnacle Associates Ltd., FMR LLC, Aviva Holdings Ltd., UBS Asset Management Americas Inc., Credit Suisse AG and State Street Corp. Company insiders that have bought Esperion Therapeutics stock in the last two years include Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy Esperion Therapeutics stock?
Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Esperion Therapeutics stock cost?
One share of Esperion Therapeutics stock can currently be purchased for approximately $33.19.
Earnings History for Esperion Therapeutics (NASDAQ:ESPR)Earnings History by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)
Current Year EPS Consensus Estimate: $-6.69 EPS
Next Year EPS Consensus Estimate: $-4.36 EPS
Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)
Insider Ownership Percentage: 35.40%Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)
Institutional Ownership Percentage: 64.65%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/22/2017||Dov A Md Goldstein||Director||Sell||800,000||$41.66||$33,328,000.00|| |
|3/21/2017||Gilbert S Omenn||Director||Buy||1,000||$42.26||$42,260.00|| |
|11/1/2016||Narendra D Lalwani||COO||Buy||5,000||$9.93||$49,650.00|| |
|7/6/2016||Mark E Mcgovern||Director||Buy||5,000||$10.00||$50,000.00|| |
|5/4/2016||Timothy M Mayleben||CEO||Buy||7,000||$14.85||$103,950.00|| |
|3/1/2016||Gilbert S Omenn||Director||Buy||5,000||$15.28||$76,400.00|| |
|1/27/2016||Timothy M Mayleben||CEO||Buy||3,600||$15.88||$57,168.00|| |
|1/15/2016||Timothy M Mayleben||CEO||Buy||7,200||$14.08||$101,376.00|| |
|4/24/2015||Dov A Md Goldstein||Director||Sell||217,469||$108.22||$23,534,495.18|| |
|11/18/2014||Patrick G Enright||Director||Sell||487,130||$32.78||$15,968,121.40|| |
|10/21/2014||Parters Vii L P Domain||Major Shareholder||Buy||500,000||$20.00||$10,000,000.00|| |
|10/7/2014||Longitude Capital Partners, Ll||Major Shareholder||Sell||11,927||$30.04||$358,287.08|| |
|7/1/2013||Brian H Dovey||Major Shareholder||Buy||285,714||$14.00||$3,999,996.00|| |
|7/1/2013||Daniel Janney||Director||Buy||235,714||$14.00||$3,299,996.00|| |
|7/1/2013||Roger S Newton||Chairman||Buy||42,346||$14.00||$592,844.00|| |
|7/1/2013||Timothy M Mayleben||CEO||Buy||5,000||$14.00||$70,000.00|| |
Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
|Esperion Therapeutics Inc (ESPR) Receives Consensus Rating of "Buy" from Brokerages|
www.americanbankingnews.com - May 22 at 2:17 PM
|Esperion Provides Update on Common Stock Trading Activity|
finance.yahoo.com - May 22 at 11:42 AM
|Esperion Therapeutics: Up, Up, And Away? - Seeking Alpha|
seekingalpha.com - May 19 at 9:51 PM
|Esperion to Participate in Fireside Chat at the UBS Global Healthcare Conference|
finance.yahoo.com - May 19 at 4:49 PM
|Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)|
finance.yahoo.com - May 19 at 5:19 AM
|Esperion to Participate in Fireside Chat at the Bank of America Merrill Lynch 2017 Healthcare Conference|
finance.yahoo.com - May 12 at 5:34 PM
|Esperion Therapeutics Inc (ESPR) Rating Increased to Hold at Zacks Investment Research|
www.americanbankingnews.com - May 9 at 7:30 PM
|Today's Research Report on Biotech Stocks to Watch: Immunomedics and Esperion Therapeutics|
finance.yahoo.com - May 8 at 9:08 AM
|Why Esperion Therapeutics Shares Were Flat In April|
finance.yahoo.com - May 6 at 10:37 AM
|Esperion Therapeutics reports 1Q loss|
finance.yahoo.com - May 5 at 5:16 PM
|Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results|
finance.yahoo.com - May 4 at 5:11 PM
|Zacks: Analysts Anticipate Esperion Therapeutics Inc (ESPR) Will Announce Earnings of -$1.48 Per Share|
www.americanbankingnews.com - May 4 at 1:26 PM
|Esperion Therapeutics (ESPR) Receiving Somewhat Positive Press Coverage, Analysis Finds|
www.americanbankingnews.com - May 2 at 9:52 AM
|Esperion Therapeutics Inc (ESPR) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - May 1 at 9:30 PM
|Somewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Stock Price|
www.americanbankingnews.com - April 29 at 12:53 PM
|Esperion Therapeutics Inc (ESPR) to Release Earnings on Monday|
www.americanbankingnews.com - April 29 at 7:09 AM
|Esperion Therapeutics (ESPR) Receives Daily Coverage Optimism Score of 0.20|
www.americanbankingnews.com - April 27 at 1:11 AM
|Esperion Therapeutics Inc (ESPR) Given Average Rating of "Buy" by Brokerages|
www.americanbankingnews.com - April 25 at 2:50 PM
|Esperion Therapeutics (ESPR) Earns News Impact Rating of 0.15|
www.americanbankingnews.com - April 23 at 10:02 PM
|Esperion Therapeutics (ESPR) Getting Somewhat Favorable Press Coverage, AlphaOne Reports|
www.americanbankingnews.com - April 20 at 9:47 PM
|3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich|
finance.yahoo.com - April 19 at 12:13 PM
|Somewhat Positive News Coverage Very Likely to Affect Esperion Therapeutics (ESPR) Share Price|
www.americanbankingnews.com - April 17 at 10:16 PM
|Royal Bank of Canada Reaffirms Hold Rating for Esperion Therapeutics Inc (ESPR)|
www.americanbankingnews.com - April 16 at 12:52 PM
|Somewhat Favorable Press Coverage Extremely Likely to Impact Esperion Therapeutics (ESPR) Share Price|
www.americanbankingnews.com - April 14 at 9:09 PM
|Zacks: Analysts Expect Esperion Therapeutics Inc (ESPR) to Announce -$1.48 EPS|
www.americanbankingnews.com - April 13 at 11:22 AM
|Cardiovascular Players Could Be Eyeing Esperion|
www.benzinga.com - April 11 at 4:53 PM
|Regeneron's Evinacumab Gets Breakthrough Designation (REGN)|
www.investopedia.com - April 7 at 9:42 AM
|The 3 Best Cholesterol Drug Stocks to Buy in 2017|
www.fool.com - March 30 at 5:30 PM
|Esperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare Conference|
finance.yahoo.com - March 28 at 4:44 PM
|JPMorgan Chase & Co. Increases Esperion Therapeutics Inc (ESPR) Price Target to $50.00|
www.americanbankingnews.com - March 27 at 10:25 AM
|Citigroup Inc Raises Esperion Therapeutics Inc (ESPR) Price Target to $77.00|
www.americanbankingnews.com - March 25 at 9:33 AM
|Dov A. Md Goldstein Sells 800,000 Shares of Esperion Therapeutics Inc (ESPR) Stock|
www.americanbankingnews.com - March 23 at 7:35 PM
|Insider Buying: Esperion Therapeutics Inc (ESPR) Director Purchases 1,000 Shares of Stock|
www.americanbankingnews.com - March 22 at 10:52 AM
|Esperion Therapeutics Inc (ESPR) Given a $39.00 Price Target by Citigroup Inc Analysts|
www.americanbankingnews.com - March 21 at 4:25 PM
|Esperion Therapeutics' (ESPR) Hold Rating Reaffirmed at JPMorgan Chase & Co.|
www.americanbankingnews.com - March 21 at 3:03 PM
|Esperion Therapeutics Inc (ESPR) Price Target Raised to $50.00 at JPMorgan Chase & Co.|
www.americanbankingnews.com - March 21 at 11:34 AM
|Esperion Gets FDA Nod for LDL-C Program (ESPR)|
www.investopedia.com - March 20 at 7:34 PM
|Esperion Therapeutics upgraded by Credit Suisse|
us.rd.yahoo.com - March 20 at 7:34 PM
|Esperion Therapeutics stock surges 52% after it says the FDA gave its drug program positive feedback|
us.rd.yahoo.com - March 20 at 7:34 PM
|Esperion Gets FDA Nod for Cholesterol Drug Program|
us.rd.yahoo.com - March 20 at 7:34 PM
|Here's What Pushed Esperion Therapeutics Inc Stock Higher Today|
www.fool.com - March 20 at 7:34 PM
|After-hours buzz: ESPR, NKTR, MMSI & more|
www.cnbc.com - March 20 at 7:34 PM
|Royal Bank of Canada Reiterates Hold Rating for Esperion Therapeutics Inc (ESPR)|
www.americanbankingnews.com - March 20 at 4:24 PM
|Esperion Therapeutics Inc (ESPR) PT Raised to $58.00|
www.americanbankingnews.com - March 20 at 1:43 PM
|Esperion Therapeutics Inc (ESPR) Raised to "Neutral" at Credit Suisse Group AG|
www.americanbankingnews.com - March 20 at 12:16 PM
|Here's Why Amgen, The Medicines Company, and Esperion Therapeutics Are All Tanking Today - Motley Fool|
www.fool.com - March 18 at 10:16 AM
|Esperion Falls Victim To Amgen's Poor Repatha Results|
www.benzinga.com - March 17 at 10:24 PM
|Amgen Tanks On Heart Study; Shares Of Other Drugmakers Tumble|
us.rd.yahoo.com - March 17 at 5:23 PM
|Esperion Therapeutics Inc (ESPR) PT Set at $39.00 by Citigroup Inc|
www.americanbankingnews.com - March 13 at 4:28 PM
|Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6% - Nasdaq|
www.nasdaq.com - March 10 at 6:09 PM
Esperion Therapeutics (ESPR) Chart for Wednesday, May, 24, 2017